Possible Spironolactone Induced Intracranial Hypertension in a Patient with Androgenetic Alopecia: A Case Report
Hamad Albraidi1, †, Omar Alzuman1, †, Abdulmajeed Alajlan2, *
Identifiers and Pagination:Year: 2018
First Page: 1
Last Page: 4
Publisher Id: TODJ-12-1
Article History:Received Date: 11/11/2017
Revision Received Date: 7/12/2017
Acceptance Date: 27/12/2017
Electronic publication date: 22/01/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Spironolactone is a well-known drug with many indications. In dermatology, it may be used for treating androgenetic alopecia with a high androgen level. A patient with idiopathic papilledema that was inactive for many years experienced a significant increase in intracranial pressure after receiving spironolactone. The symptoms were resolved soon after the medication was discontinued. This report draws physicians’ attention to such rare adverse events that may have unwanted consequences.